MARKET

ONCT

ONCT

Oncternal Therapeutics Inc
NASDAQ
7.45
-0.23
-2.99%
Opening 12:56 07/15 EDT
OPEN
7.77
PREV CLOSE
7.68
HIGH
7.77
LOW
7.00
VOLUME
3.00K
TURNOVER
0
52 WEEK HIGH
13.14
52 WEEK LOW
5.57
MARKET CAP
22.05M
P/E (TTM)
-0.6032
1D
5D
1M
3M
1Y
5Y
1D
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
Oncternal Therapeutics, Inc. Is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies. James Breitmeyer will present at the JonesTrading Healthcare Seaside Summit being held July 14-16, 2024 in San Diego.
Barchart · 4d ago
Weekly Report: what happened at ONCT last week (0701-0705)?
Weekly Report · 07/08 11:45
Weekly Report: what happened at ONCT last week (0624-0628)?
Weekly Report · 07/01 11:46
Weekly Report: what happened at ONCT last week (0617-0621)?
Weekly Report · 06/24 11:55
Weekly Report: what happened at ONCT last week (0610-0614)?
Weekly Report · 06/17 11:44
Weekly Report: what happened at ONCT last week (0603-0607)?
Weekly Report · 06/10 11:47
Weekly Report: what happened at ONCT last week (0527-0531)?
Weekly Report · 06/03 11:50
Analysts Offer Insights on Healthcare Companies: Springworks Therapeutics (SWTX), Cyclo Therapeutics (CYTH) and Oncternal Therapeutics (ONCT)
TipRanks · 05/31 10:30
More
About ONCT
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.

Webull offers Oncternal Therapeutics Inc stock information, including NASDAQ: ONCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONCT stock methods without spending real money on the virtual paper trading platform.